Sexual HealthStrong Evidence

PT-141

Also known as: Bremelanotide, Vyleesi

Melanocortin receptor agonist that enhances sexual arousal and desire through central nervous system activation.

Benefits

Conditions

Evidence

FDA-approved, multiple clinical trials+ studies

Source

Synthetic α-MSH analog

Gabriel Brain Score

Moderate

Overview

Melanocortin receptor agonist that enhances sexual arousal and desire through central nervous system activation.

Mechanism of Action

Activates MC3R and MC4R melanocortin receptors in hypothalamus, increases dopamine release for libido enhancement, sends neuronal impulses via spinal cord for arousal, works centrally (not via peripheral vasodilation).

Key Benefits

✓Increases sexual desire and arousal in both sexes
✓Works via CNS (not dependent on vascular function)
✓Effective for psychological/central causes of dysfunction
✓FDA approved for female HSDD
✓Rapid onset (30-60 minutes)

Clinical Applications

Hypoactive sexual desire disorder (HSDD)Erectile dysfunction (especially non-vascular)Low libidoArousal disordersSexual dysfunction from antidepressants

Dosing Guidelines

Subcutaneous injection

Typical Dose1.75 mg

FrequencyAs needed, at least 45 min before sexual activity

DurationSingle dose per event, max 8 doses/month

Intranasal

Typical Dose0.5-2 mg

FrequencyAs needed before activity

DurationSingle dose per event

* Dosing should be individualized. Always consult with a qualified healthcare practitioner.

Research & Evidence

Evidence Level

Strong

Studies

FDA-approved, multiple clinical trials

Summary

FDA approved for premenopausal women with HSDD. Clinical trials demonstrate efficacy in both sexes. Good safety profile. Unique mechanism compared to PDE5 inhibitors.

Safety Information

Potential Side Effects

•Nausea
•Flushing
•Headache
•Transient blood pressure increase
•Injection site reactions

Contraindications

Uncontrolled hypertension
Cardiovascular disease
Pregnancy
Breastfeeding

Interactions

⚠Caution with blood pressure medications

Quick Facts

CategorySexual Health

SourceSynthetic α-MSH analog

Legal StatusFDA approved as Vyleesi for female HSDD; compounded for off-label use

Gabriel Brain Score

84/ 100

Source Your Protocol

Our preferred peptide partner offers lab-tested, COA-verified peptides with optional physician oversight. Sourced from US-regulated facilities.

Related Peptides

Bremelanotide

FDA-approved melanocortin receptor agonist for female hypoactive sexual desire disorder.

StrongLearn more →